Jon Stewart and Lina Khan discuss how pharma companies build patent thickets.

NEWS: @tahiramin.bsky.social sat down with Nick Robertson of MLex to discuss how we’re helping Congress and the public understand the connection between patent abuse and high drug prices. Read the interview: www.mlex.com/mlex/article...

In our November newsletter, @tahiramin.bsky.social discusses findings from a new nationwide survey we commissioned from the Center for Opinion Research at Franklin and Marshall College. www.i-mak.org/2025/11/10/n...

Sen. @hassan.senate.gov (D-NH): What are the real impacts of these patent games on patients? Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.

Senator Susan Collins (R-ME) took time during a recent hearing on 340B reform to highlight the importance of patent reform.

Last week, the Senate HELP Committee held a hearing on 340B reform. During the hearing, Sen. Hawley (R-MO) asked @wbfeldman.bsky.social how we can lower drug prices for Americans. Dr. Feldman outlined several steps we can take while making clear that patent reform is critical.

TrumpRx and a most-favored nation policy won’t lower drug prices for patients. We need a government that is willing to stand up to corporate interests and actually become a most favored nation for patients, not pharmaceutical profits. New op-ed for @statnews.com ↓ www.statnews.com/2025/10/24/t...

Thank to our colleagues of @imakglobal.bsky.social for this strong analyse : www.statnews.com/2025/10/24/t...

🚨NEW: @nytimes.com reports on Colorado’s effort to curb the price of Enbrel. “The fact the government never stepped in to rectify this extended patent monopoly is a case to be studied.” - @tahiramin.bsky.social www.nytimes.com/2025/10/23/h...

🗞️ @statnews.com highlights key findings from a new national survey we commissioned to understand Americans’ top concerns on drug pricing. 🔗 www.statnews.com/pharmalot/20...

⏰ Our webinar is starting in 1 hour! Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform. Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social

In our October newsletter, @tahiramin.bsky.social asks a simple but critical questions about Merck's Keytruda Qlex: does it really count as an invention? www.i-mak.org/2025/10/17/k...

4 in 5 Americans support changes to patent laws to address drug pricing Join us tomorrow at 10AM ET for a webinar unpacking results from a new national survey showing strong bipartisan support for patent reform. RSVP here: www.i-mak.org/survey/

Did you RSVP to our webinar? A new national survey reveals bipartisan support for patent system reforms 🗓️ Wednesday, October 22 🕙 10AM ET 🗣️ @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social 🎟️ www.i-mak.org/survey/

Looking forward to this conversation about drug prices next week!

JOIN US! On Wednesday, October 22 at 10AM ET we will host a webinar to discuss results from a new national survey revealing bipartisan momentum for patent system reform. Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social RSVP! www.i-mak.org/survey/

Swipe to see how readers are reacting 👇

🚨 @washingtonpost.com reports on Colorado’s effort to lower the price of Enbrel—the latest state-level move to curb patent abuse in order to make life-saving drugs affordable for the patients that need them. The article features data from our team at I-MAK. www.washingtonpost.com/health/2025/...

Merck is launching a patent-protected injectable version of Keytruda before biosimilars of the IV version of Keytruda enter the market. Swipe to see reactions to the recent @nytimes.com story on Merck's product hopping scheme.

“Merck is just the latest in a long line of drug companies that have introduced new versions of their medicines that allow them to keep charging high prices [to patients] even as their original patents expire.” www.seattletimes.com/nation-world...

1️⃣ Read The New York Time’s new investigation into Merck’s product hop on Keytruda. 2️⃣ Watch the video be published back in May detailing exactly how Merck is doing it.

@nytimes.com investigates Merck’s product hop on the cancer drug Keytruda. “Merck has sought nearly 300 patents related to Keytruda, according to I-MAK. (Merck disputed I-MAK’s count but declined to provide a different figure.)" www.nytimes.com/2025/09/19/h...

🚨BREAKING: The New York Times investigates Merck’s product hop on Keytruda.

We have extensive data detailing Merck’s patenting tactics on Keytruda. I will share more here soon.

My team at @imakglobal.bsky.social has been warning for years that Merck would game the patent system to product hop its blockbuster cancer drug Keytruda. Today, the New York Times published an investigation into the company’s tactics. www.nytimes.com/2025/09/19/h...

Our September newsletter is out! In it, @tahiramin.bsky.social breaks down two bipartisan bills seeking to address patent abuse so medicines can be more affordable for patients 📄The ETHIC Act 📄The Medication Affordability and Patent Integrity Act www.i-mak.org/2025/09/18/s...

A new study in @jama.com by Dongzhe Hong, @seansst5.bsky.social‬, and Reed F. Beall looks at the cost of extended market exclusivities due to patent term extensions and patent gaming. jamanetwork.com/journals/jam...

“History will not remember how profitable our cures were, only how many were left to die waiting for them.” - Jonathan Lee, B.A., B.S., UC Berkeley www.bcphreview.org/article/1412...

MedPath unpacked key findings from our latest Overpatented, Overpriced report. 📊Read our report: www.i-mak.org/overpatented/ 📄Read MedPath's analysis: trial.medpath.com/news/1926871...

AbbVie used its patent thicket to block six competitors from launching cheaper versions of a $220,000 cancer drug.

SEN. BLUMENTHAL: Do all of you agree that reforms in the patent laws would enable lower costs for consumers? …Yes …Yes …Yes …Yes

NYU Law Professor Daniel Francis is right. A drug company “has every incentive to overlist patents [in the FDA’s Orange Book] because it deters generic entry.” What is a 30-month stay and how do drug companies game it? 🧵

NEWS: Senators @welch.senate.gov (D-VT), Josh Hawley (R-MO), and @klobuchar.senate.gov (D-MN) introduced the Eliminating Thickets to Improve Competition (ETHIC) Act. So, what is the ETHIC Act?🧵

AbbVie offered technical employees iPhones, iPads, and Apple computers as rewards for coming up with new ideas to "increase the patent coverage for Humira."

In a recent FTC listening session, Hans Sauer of BIO suggested that pharma execs don’t coordinate with lawyers to strategically use patents to block competition. I guess he forgot about the Congressional investigation exposing how AbbVie hired McKinsey to do exactly that.

SEN. PETER WELCH (D-VT): For decades, Big Pharma has exploited U.S. courts and the patent system through anticompetitive practices that prevent generic and biosimilar competitors from entering the market, forcing Vermonters to pay more out of pocket for lifesaving drugs www.axios.com/pro/health-c...

Theresa Schliep of @law360.bsky.social reports on the ETHIC Act ⤵️ "[A] report released in April by the Initiative for Medicines, Access and Knowledge, an advocacy group, said the two major pharmaceutical companies behind leading GLP-1 products are leveraging patent thickets to delay competition.”

⌛️ Time is running out to reserve your spot for this upcoming conversation with @tahiramin.bsky.social of @imakglobal.bsky.social! 🔗 RSVP today: attendee.gotowebinar.com/register/522...

How does the U.S. patent system shape drug prices? And who profits? Join us on July 22 at 11AM ET for a virtual conversation hosted by @capitolforum.bsky.social RSVP: register.gotowebinar.com/register/522...

Thank you to The Plus SideZ podcast for having me on to talk about the patent system and how the pharma industry’s abuse of it keeps GLP-1 prices so high.

💊 How does the U.S. patent system shape drug prices? And who profits? Join us Tuesday, July 22 at 11:00 a.m. EDT for more on these topics with @tahiramin.bsky.social, co-founder and CEO of @imakglobal.bsky.social. 🔗 RSVP: attendee.gotowebinar.com/register/522...

Join us! Stop Skyrocketing Drug Prices: A Briefing on Patents and Drug Prices 🗓️ July 30 🕛 12-1PM ET 🏛️ Rayburn House Office Building, Room 2237 Speakers: @tahiramin.bsky.social, Patricia Kelmar, Wayne Brough, and Christy Robinson Hosted by @rstreet.bsky.social and PIRG

Join us on July 15 in Washington DC for The Kaiser Permanente Institute for Health Policy's forum, "A Path to Fair Drug Pricing: Examining Competition, Value, and Access." 🗓️ July 15 🕘 9am - 2:15pm ET 📍 The Center for Total Health www.kpihp.org/ihp_events/a...

NIALL STANAGE: 83% of all Americans, including 84% of Democrats and 89% of Republicans, said in a 2023 poll that Big Pharma’s profits are a major reason why prescription drugs cost so much.

TAHIR AMIN (@tahiramin.bsky.social): I think progress is being made [on drug pricing and patent reform]...Not quick enough…We need to get further upstream to the root of the problem…It’s starting with the drug companies and how they use the patent system. That is what gives them the power.

TAHIR AMIN (@tahiramin.bsky.social): There is a concern on both sides of the aisle that the lack of competition [in the pharma industry] is actually driving prices up.

TAHIR AMIN (@tahiramin.bsky.social): Novo Nordisk spends more on buying back shares and paying off its shareholders than it does on R&D…This idea that [pharma companies] need to charge higher prices so they can do the R&D is actually not entirely true.

TAHIR AMIN (@tahiramin.bsky.social): It’s important for the public to really become more and more in tune with how the [pharma] companies are using the patent system for their own gain and not as it was originally intended…its become an ATM.

Our own @tahiramin.bsky.social joined The Hill’s Niall Stanage to discuss what we uncovered in our latest report.

“We want to expose how the patent system has become a tool to drive the business model and financial gain…It’s a corruption of the patent system” @tahiramin.bsky.social walks through our new Overpatented, Overpriced report with @levernews.com www.levernews.com/drugmakers-s...